

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**The development and pilot testing of a patient decision aid to help patients with ulcerative colitis choose between ongoing medical treatment and surgical treatment options: protocol for the DISCUSS study.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031845
Article Type:	Protocol
Date Submitted by the Author:	21-May-2019
Complete List of Authors:	Baker, Daniel; Leicester Medical School, Lee, Matthew; Sheffield Teaching Hospitals NHS Foundation Trust Folan, Anne-Mairead; Leeds Beckett University, Department of Psychology Blackwell, Sue ; ACPGBI patient Liaison group Robinson, Kerry; Sheffield Teaching Hospitals NHS Foundation Trust, Inflammatory Bowel Disease nurse specialist Wootton, Rebecca; Sheffield Teaching Hospitals NHS Foundation Trust, Stoma Care Specialist Nurse Sebastian, Shaji; Hull and East Yorkshire Hospitals NHS Trust, Department of Gastroenterology Brown, Steven; Sheffield Teaching Hospitals NHS Foundation Trust, Department of General Surgery Jones, Georgina; Leeds Beckett University Faculty of Health and Social Sciences, Lobo, Alan J ; Royal Hallamshire Hospital, Gastroenterology Unit
Keywords:	Ulcerative Colitis, Decision Making, SURGERY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title:** The development and pilot testing of a patient decision aid to help patients with  
4 ulcerative colitis choose between ongoing medical treatment and surgical treatment options:  
5 protocol for the DISCUSS study.  
6  
7

8  
9 **Authors:** Baker DM, Lee MJ, Folan AM, Blackwell S, Robinson K, Wootton R, Shaji S, Brown SR,  
10 Jones GJ, Lobo AJ  
11

12  
13 **Correspondence author:**  
14

15  
16 Professor Alan Lobo, [alan.loblo@sth.nhs.uk](mailto:alan.loblo@sth.nhs.uk), 01142712353  
17

18 Gastroenterology Unit, P Floor, Royal Hallamshire Hospital, Sheffield, S10 2JF  
19

20  
21 **Co-authors:**  
22

23 Mr Daniel M Baker, Medical School, University of Leicester, Leicester, UK  
24

25 Miss Sue Blackwell, Patient Liaison Group, ACPGBI  
26

27 Professor Steven R Brown, Department of General Surgery, Sheffield Teaching Hospitals,  
28 Sheffield, UK  
29

30 Miss Anne-Mairead Folan, Department of Psychology, School of Social Sciences, Leeds Beckett  
31 University, Leeds, UK  
32

33 Professor Georgina L Jones, Department of Psychology, School of Social Sciences, Leeds  
34 Beckett University, Leeds, UK  
35

36 Mr Matthew J Lee, Department of General Surgery, Sheffield Teaching Hospitals, Sheffield,  
37 UK  
38

39 Professor Shaji Sebastian, Department of Gastroenterology, Hull and East Yorkshire Hospitals  
40 NHS Trust, Hull, UK  
41

42 Mrs Kerry Robinson, Inflammatory Bowel Disease Nurse Specialist, Sheffield Teaching  
43 Hospitals, Sheffield, UK  
44

45 Mrs Rebecca Wootton, Stoma Care Specialist Nurse, Sheffield Teaching Hospitals, Sheffield,  
46 UK  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Professor Alan J. Lobo, Academic Dept of Gastroenterology, University of Sheffield and  
4 Sheffield Teaching Hospitals NHS Foundation Trust.  
5  
6

7 **Word count: 3041**  
8  
9

## 10 **Abstract**

11  
12

13 Introduction: Approximately 20-30% of patients with Ulcerative Colitis (UC) require surgery,  
14 the majority of these being elective due to chronic symptoms refractory to medical  
15 treatment. The decision for surgery is a difficult one and one dependant on patient  
16 preferences. Current resources for patients considering surgery have been found not to meet  
17 minimum international standards. The overall aim of the 'DISCUSS' study is to develop and  
18 evaluate a new Patient Decision Aid (PtDA) for patients considering surgery for UC created in  
19 line with international minimum standards.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Methods and analysis: This is a prospective mixed-methods study of adults (18+ years) who  
32 are considering surgical intervention for UC across two regional centres in Yorkshire, UK. This  
33 study is in 3 stages. In stage 1 we will develop the PtDA via systematics reviews and a patient  
34 questionnaire to inform content of the PtDA. In stage 2 we will assess the face validity of the  
35 PtDA using mixed-methods on key stakeholders using both semi-structured interviews and  
36 questionnaires, following which the PtDA will be refined. In stage 3 we will assess the  
37 acceptability of using the PtDA in clinical practice. This will use a mixed-methods approach on  
38 clinicians using the PtDA and patients who are considering undergoing elective surgery.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 Ethics and Dissemination: Research Ethics approval (Ref: 19/NE/0073) and Health Research  
4  
5 Authority approval (Ref: 257044) have been granted. Results will be published in open access  
6  
7 peer-reviewed journals, presented and conferences and distributed through the Crohn's and  
8  
9 Colitis UK charity. External endorsement will be sought from the International Patient  
10  
11 Decision Aid Standards (IPDAS) Collaboration inventory of PtDAs.  
12  
13  
14  
15

## 16 **Article summary;**

17  
18  
19 Strengths and limitations of this study:  
20  
21

- 22  
23 ● This study will develop and evaluate a new patient decision aid for patients  
24  
25 considering surgery for ulcerative colitis which will meet minimum international  
26  
27 standards. This is a preliminary pilot study.  
28
- 29  
30 ● This study will provide evidence for its acceptability and value to patients in routine  
31  
32 clinical practice when considering surgery for ulcerative colitis.  
33
- 34  
35 ● This study will also provide evidence of the acceptability of the patient decision aid  
36  
37 from the clinicians' perspective and the feasibility of use in routine clinical practice.  
38
- 39  
40 ● This study will not provide evidence on the value of the PtDA nationally. However, it  
41  
42 will provide evidence across two large regional centres in Yorkshire which may be  
43  
44 utilised to form the study design of a national evaluation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

### The rationale for the study

Ulcerative colitis (UC) is a chronic, relapsing and remitting inflammatory condition of the colon and rectum. It causes debilitating symptoms such as bleeding per rectum, increased stool frequency, abdominal pain and tenesmus (1). Symptoms can be managed using medical therapies such as aminosalicylates, corticosteroids, biologics agents (anti-tumour necrosis factor- $\alpha$  or anti-integrin) and tofacitinib (2-5). However approximately 20-30% of patients with UC will require surgery during their disease course (6). A minority of patients will require emergency surgery – but the majority of patients have elective surgery due to chronic symptoms, refractory to medical treatment (7). Individuals therefore make a choice, or series of choices, to continue with medical treatment or undergo surgery. Surgery may be undertaken with the intention of proceeding to further reconstructive surgery to restore continuity of the gastrointestinal tract, or remaining with a permanent ileostomy.

The decision to opt for elective surgery is described as preference-sensitive as the preferred treatment option is dependent on patient preferences due to clinical equipoise between the options (8). The same can be said for the decision between reconstructive surgery versus permanent ileostomy. The impact on lifestyle of these two choices cannot be understated – reconstructive surgery will avoid a stoma, with an acceptance of potential complications such as increased stool frequency, pouchitis or faecal incontinence (9). A stoma may offer more control over excretory functions, but is associated with complications such as parastomal hernia, as well as psychological sequelae (10,11). When selecting a treatment option, it is clear that the patient must select the option based on their preferences.

1  
2  
3  
4  
5  
6 Shared decision-making is a process whereby clinicians share information about treatment  
7  
8 options, empowering the patient to make a decision based on their preferences (12).  
9  
10 Providing clear and balanced pre-operative information is a major prerequisite to informed  
11  
12 decision making (12,13). National Institute for Health and Care Excellence (NICE) guidelines  
13  
14 for UC emphasise the importance of providing such information, but note that no high quality  
15  
16 studies assessing the desired content of information were available on which to base  
17  
18 recommendations (14). As such clinicians lack guidance on patient informational preferences  
19  
20 on which to base discussions during consultations. Clinician preferences can be misaligned  
21  
22 with patient preferences, especially when considering surgical options for UC (15), forming a  
23  
24 barrier to decision-making in this population. Pre-operative discussions may also be limited  
25  
26 by 'implicit persuasion' – a process whereby clinicians subconsciously place greater emphasis  
27  
28 on treatment options they believe are suited to the patient (16). Lack of time in clinic, as well  
29  
30 as the lack of guidance on the content of pre-operative consultations, may provide limitations  
31  
32 in the shared decision-making process for UC patients (17).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Patient decision aids**

44  
45 Patient decision aids (PtDAs) are specially created tools which aim to improve patient  
46  
47 knowledge and aid decision-making (18,19). They are evidenced based, utilising the most up-  
48  
49 to-date clinical evidence, studies assessing patient informational preferences and evidence  
50  
51 on how patients make decisions (20). PtDAs can be used within the clinical encounter, by the  
52  
53 clinician, to provide structure to consultations, but also by the patients outside the encounter  
54  
55 to aid their deliberation – a key step to informed consent (13).  
56  
57  
58  
59  
60

1  
2  
3 A systematic review of PtDAs in surgery has illustrated their role in improving knowledge,  
4 reducing decisional conflict and increasing patient input into decision making (21). A  
5  
6 satisfactory PtDA for patients considering surgery for UC is not currently available. The single  
7  
8 aid registered on the Decision Aids Library Inventory (22) does not meet minimum standards  
9  
10 laid out by the International Patient Decision Aid Standards (IPDAS) (23), which have  
11  
12 established clear guidance for the systematic development of a PtDA (24). This can be  
13  
14 summarised into 3 stages, as previously described by members of our research group (25),  
15  
16 and forms the methodology behind this protocol. It is therefore proposed that a new PtDA  
17  
18 for patients considering surgery for UC, created in-line with minimum standards, will work  
19  
20 towards filling an informational need for both patients and clinicians (14,26).  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Aims and objectives**

30  
31  
32 The aim of this research is to develop, assess and validate a patient decision aid for patients  
33  
34 considering elective surgery for ulcerative colitis; i.e. whether to continue with their current  
35  
36 medical treatment, or whether to undergo surgery. This will also include information on the  
37  
38 different surgical options (mainly permanent stomas vs reconstructive surgery) as this may  
39  
40 influence the overall decision to undergo surgery. We will do this in line with the systematic  
41  
42 development process specified by IPDAS, ensuring the decision aid meets minimum standards  
43  
44 (24,27).  
45  
46  
47  
48  
49

50 The study objectives are to:

- 51  
52  
53 1. Develop a decision aid for use by gastroenterology and colorectal surgery teams  
54  
55 (consultant surgeons/gastroenterologists, stoma/IBD nurses) to support patients in  
56  
57 their decision about elective surgery, and the surgical option they may wish to opt for.  
58  
59  
60



- 1
- 2
- 3 2. Assess the face validity of the decision aid to support patients make an informed
- 4 decision about their preferred treatment option.
- 5
- 6
- 7
- 8 3. Pilot an evaluation study for the acceptability of the decision aid in clinical practice.
- 9

10 This will use a mixed methods approach to capture the views of:

- 11
- 12
- 13 a. patients making the treatment decision and
- 14
- 15 b. gastroenterology and colorectal surgery health professionals supporting the
- 16 patient through their decision.
- 17
- 18
- 19
- 20

21 It is anticipated the evaluation of the PtDA will determine whether the administration of a  
22 PtDA in the treatment pathway will better support patients in their treatment decisions, as  
23 well as providing structure and guidance to consultations with patients.  
24  
25  
26  
27

## 28 **METHODS AND ANALYSIS**

29  
30  
31  
32 The methodology used for this research has been adapted from a previously published  
33 protocol to develop a PtDA for women with cancer to help them make fertility preservation  
34 treatment decisions (Cancer, Fertility and Me), led by a member of our research team (GLJ)  
35 and funded by Yorkshire Cancer Research (S391) (25). The protocol also follows established  
36 guidance from IPDAS and other recommended guidance regarding the development of PtDA  
37 (24,27). The study process is summarised in figure 1.  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 A steering group with relevant expertise to support PtDA development is essential (24).  
48 Therefore, a steering group was created prior to protocol development and submission for  
49 grant funding to ensure all stakeholders were represented. The steering group consists of;  
50 specialist surgical and gastroenterology clinicians, health psychologists with expertise in  
51 decision-making, IBD/Stoma nurses, a medical student, and patient representatives. All  
52 sections of the protocol have been reviewed and discussed by the steering group. The PtDA  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 will be developed across two regional centres (Sheffield Teaching Hospitals and Hull and East  
4 Yorkshire Hospitals). The steering group will hold regular meetings during stage 1 to decide  
5  
6 the content and design of the aid, and will hold regular meetings at important stages  
7  
8 thereafter. Ethics approval was granted on 13<sup>th</sup> March 2019.  
9  
10  
11  
12

## 13 **Design**

### 14 Stage 1: Development of the PtDA

#### 15 *1. Validating patient informational preferences*

16  
17 Our group has already carried out qualitative work exploring patient informational  
18 preferences when considering surgery (26). These results will be validated on a national scale  
19 by a questionnaire using established methodology (15,28). Questionnaire content will include  
20 demographic data, the control preferences scale (29) and questions about the preferred  
21 content and format of pre-operative information. This will provide a description of whether  
22 particular demographic groups of patients are amenable to a PtDA, and the preferred content  
23 and format of such an aid. Questionnaires will be disseminated to a number of sites through  
24 an established network of IBD researchers. Prior to questionnaire development, patients will  
25 be involved in questionnaire design and refinement via a focus group held at Sheffield  
26 Teaching Hospitals. This will help make the findings generalisable and ensure key concepts  
27 are included within the questionnaire.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 *2. Synthesising the best available evidence*

50 This will consist of the following stages:

- 51 a) Systematic reviews of evidence about the risks and benefits of elective surgery and  
52 continued medical management will be undertaken:  
53  
54  
55  
56  
57  
58  
59  
60

- A systematic review of outcomes after surgery to inform the PtDA using the best available evidence. Methodology will include the procedures subtotal colectomy with permanent end ileostomy, proctocolectomy, ileal-anal pouch anastomosis and ileorectal anastomosis. Ileorectal anastomosis will be included in the PtDA as our research group notes it is a procedure that is offered in some UK centres, as well as in centres outside the UK. Its inclusion is with the caveat that some centres may not offer this operation, and this will be noted in the aid. Primary outcome will be quality of life, with secondary outcomes covering a wide range of early and late complications after surgery.
  - Systematic review of risks and benefits of continued medical treatment. This will inform the decision aid so that the consequences of continued medical treatment – positive and adverse – can be quantified for patients facing this choice.
  - Systematic review of the factors that may facilitate or hinder patients with UC to make medical and surgical treatment choices (e.g. possible fear of a stoma) to ensure these elements are captured and addressed in the new resource.
- b) Focus groups with expert clinicians, nurses and patients regarding the optimum time to introduce the PtDA into the treatment pathway, as well as the optimum content for each group. This will be via a PPI day at Sheffield Teaching Hospitals.

### 3. Drafting the PtDA

Once the evidence has been synthesised, the steering group will meet to decide the content of the aid. The PtDA will be created using IPDAS guidance (24,27); including guidance on balancing options (30), risk presentation (30–33), eliciting patient values (34), use of patient

1  
2  
3 stories (18), and enabling readability (35,36), something found to be poor in the UC patient  
4  
5 literature (23).  
6  
7

8  
9 The content of the aid will be guided by the informational preferences studies and systematic  
10  
11 reviews of evidence we complete. Significant risks, benefits and outcomes, and their  
12  
13 associated probabilities from our reviews will be included. Common topics of informational  
14  
15 preferences will be discussed by the group, and a consensus established on the inclusion. The  
16  
17 composition of the group, with both expert clinicians and patients, will help to develop  
18  
19 content that meets the requirements of both patients and healthcare professionals.  
20  
21  
22

#### 23 24 Stage 2: Face validity study 25

26  
27 The aim of this stage is to assess the PtDA for comprehension, feasibility and acceptability  
28  
29 using key stakeholders - sometimes referred as learner verification or alpha testing (24,37).  
30  
31 This will be done with both clinicians and patients, using qualitative methodology, and  
32  
33 according to an established protocol, with which we have extensive experience. This will be  
34  
35 undertaken across two large sites (Sheffield and Hull).  
36  
37  
38

#### 39 40 *Sample* 41

42  
43 A purposive sample of healthcare professionals and patients not involved in the steering  
44  
45 group will be invited to take part in the study. The HCP sample will include colorectal  
46  
47 surgeons, gastroenterologists, IBD nurses and Stoma nurses. The patient sample will include  
48  
49 those who opted for surgery, those who considered but declined surgery and those currently  
50  
51 deliberating treatment options. We expect a sample size of 20 participants, with a minimum  
52  
53 of 10 healthcare professionals and 10 patients, will be enough based on previous studies and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 experience (25). However, sample size will be guided by data saturation, which is in-line with  
4  
5 good qualitative methods (38–40).  
6  
7

### 8 *Recruitment*

9  
10  
11 Ethics will be obtained prior to recruitment. Patients will be identified through the services at  
12  
13 the two clinical centres by clinicians and nurses. We will also advertise stage 2 of the study  
14  
15 through the Crohn's and Colitis UK forums. Following this the contact details for consenting  
16  
17 patients will be passed on to a trained researcher and those willing to participate will be sent  
18  
19 the PtDA for review. Healthcare professionals will be recruited from the study sites through  
20  
21 purposive sampling. All contact details will be stored securely at either Sheffield Teaching  
22  
23 Hospitals or Leeds Beckett University.  
24  
25  
26  
27  
28

### 29 *Data collection*

#### 30 *Qualitative*

31  
32  
33 Consenting clinicians and patients will be posted the PtDA and given 1-2 weeks to assess the  
34  
35 aid, with a telephone interview taking place at the end of the time period. Patients and  
36  
37 clinicians will provide verbal feedback on the aid, focussing on its comprehensibility and ease  
38  
39 of use. An interview schedule will be created *a priori* by expert members of the steering group.  
40  
41 Interviews will be audio recorded, digitalised, and transcribed for analysis.  
42  
43  
44  
45  
46  
47

#### 48 *Quantitative*

49  
50  
51 Patients will also be asked to complete a Preparation for Decision-Making Questionnaire. The  
52  
53 Preparation for Decision-Making Questionnaire is a 10-item measure which will provide a  
54  
55 score on a scale of 0-100 (41). The higher the score, the higher the perceived levels of  
56  
57  
58  
59  
60

1  
2  
3 preparation for decision-making - which will provide a validated quantitative measure of how  
4  
5 individuals view the usefulness of the PtDA (41).  
6  
7

### 8 *Data analysis*

9  
10  
11 Interviews will be transcribed and coded using NVivo 11 Computer-Assisted Qualitative Data  
12  
13 Analysis Software (QSR International, Australia). Analysis will use an inductive thematic  
14  
15 approach, outlined by Braun and Clarke using a systematic five-step approach: familiarisation,  
16  
17 generating initial codes, searching for themes, reviewing themes, and defining and naming  
18  
19 themes (40). The themes actively generated by the researchers from the data will be  
20  
21 discussed by the steering group.  
22  
23  
24  
25

26  
27 The steering group will subsequently refine the aid based on the results of this stage. If there  
28  
29 are significant changes required, a second face validity study will be undertaken before  
30  
31 progression to stage 3.  
32  
33

### 34 35 Stage 3: Evaluation study

36  
37  
38 The aim of this pilot is to field test the PtDA in clinical practice, as there may be clinical  
39  
40 contextual factors impacting the PtDA. This is typically referred to as beta testing (24). This  
41  
42 will follow a mixed-methods approach across the same two sites as in stage 2. We aim to  
43  
44 recruit 15 patients at each site for a minimum sample size of 30 – comparable with other PtDA  
45  
46 pilots in the literature (42). A summary of stage 3 is provided in figure 2.  
47  
48  
49

### 50 51 *Quantitative*

52  
53  
54 *Sample and recruitment:* All patients over the age of 18 that receive consultation about the  
55  
56 possibility of undergoing elective surgery will be included. This includes consultations with  
57  
58 clinicians and specialist nurses. We will use the referral model for implementing PtDA - a  
59  
60

1  
2  
3 process where the clinician mentions the PtDA to eligible patients during consultation about  
4 treatment options, and indicates the clinical researchers will discuss the study following the  
5 consultation should the patient consent to involvement (43). Eligible patients identified by  
6 the clinical team will be invited to participate by the researcher(s) with the clinical team  
7 immediately following the consultation if they are present, or within a week if the patient  
8 consents to contact outside the clinical setting by a member of the research team.  
9  
10  
11  
12  
13  
14  
15  
16

17  
18 *Data measures and collection:* Patients will be asked to complete a series of questionnaires  
19 at baseline (1<sup>st</sup> clinic appointment) before administration of the PtDA. Patients will be  
20 instructed not to open or view the PtDA before completion of the questionnaires at baseline.  
21 Patients will then complete the same questionnaires at time-point 1 (immediately before the  
22 2<sup>nd</sup> clinic appointment). Questionnaires will include a measure of anxiety (STAI-6) (44), Stage  
23 of Decision-Making (45) and Decisional Conflict Scale (46) as recommended by IPDAS (24). All  
24 questionnaires will provide a quantitative measure to allow comparison before and after use  
25 of the PtDA.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 *Analysis:* Summary statistics will be reported for demographics and other relevant indicators.  
39 For decisional outcome measures we will use paired sample t-tests to calculate mean changes  
40 from baseline to time-point 1. Confidence intervals will be set at 95% *a priori*, meaning values  
41 will be significant if  $p \leq 0.05$ .  
42  
43  
44  
45  
46  
47  
48

#### 49 *Qualitative*

50  
51  
52 *Sample and recruitment:* Healthcare professionals and patients will be asked to take part in  
53 semi-structured interviews. We will undertake 10 interviews with patients and 10 with  
54 healthcare professionals (IBD/stoma nurses, gastroenterology and surgical clinicians),  
55 although this will be guided by data saturation, in line with established protocols in qualitative  
56  
57  
58  
59  
60

1  
2  
3 research (38,40). The interviews will give a deeper insight into the experience of using the aid  
4  
5 from a patient and clinician perspective in clinical practice. Clinician interviews will also  
6  
7 explore views regarding the timing of the aid in the treatment pathway, establishing if the  
8  
9 time previously eliciting in stage 1 is also the optimum time for additional sites. Patients will  
10  
11 be recruited using purposive sampling from the sample of 30 that have taken part in the  
12  
13 quantitative analysis of stage 3. Prior to interview patients will receive an information sheet,  
14  
15 and on the day of interview the patient will be issued a consent form which will be co-signed  
16  
17 with the interviewer.  
18  
19  
20  
21  
22

23 *Data collection:* An interview transcript will be created by expert members of the steering  
24  
25 group *a priori*. Questions will be adapted from the transcript used in stage 2, with additional  
26  
27 questions to add depth and clarity into the interpretation of the quantitative results.  
28  
29 Questions will also focus on the PtDAs usefulness in helping the patient decide between  
30  
31 treatment options.  
32  
33  
34  
35

36 *Analysis:* All interviews will be transcribed and coded as per the same methods in stage 2.  
37  
38 Framework analysis, an analysis designed specifically for applied health and policy research  
39  
40 (47), will be utilised to identify recurrent themes. Recurrent themes will be discussed with the  
41  
42 steering group and subsequent refinement of the PtDA will take place  
43  
44  
45  
46

## 47 **ETHICS AND DISSEMINATION**

### 48 **Ethical considerations**

49  
50  
51  
52  
53 Written, signed consent will be obtained from all participants at stages where it is necessary.  
54  
55 Participants will have the right to withdraw from the research process at any time throughout  
56  
57 the study. All interviews will be kept strictly confidential and patients and healthcare  
58  
59  
60



1  
2  
3 professionals will be given a study ID number to maintain this confidentiality. Participation in  
4  
5 this study will not interfere with usual patient care.  
6  
7

## 8 **Dissemination**

9  
10  
11 This a multidisciplinary, collaborative project with clinicians and patients. This will allow us to  
12  
13 disseminate the research and its milestones into both the NHS and the wider healthcare  
14  
15 community through a variety of local, national and international forums such as charities and  
16  
17 international meetings. We will also seek to index an online version of the PtDA in the Decision  
18  
19 Aid Library Inventory once we have completed and analysed the paper version. We will also  
20  
21 seek to index the NHS library of decision aids. A web-based version of the PtDA will also allow  
22  
23 dissemination through the internet which is widely accessible to patients worldwide. Social  
24  
25 media such as twitter and blogs can also be utilised to signpost the availability of the  
26  
27 instrument.  
28  
29  
30  
31  
32

33  
34 We plan to impact the academic and clinical community more widely through a combination  
35  
36 of conference presentations and peer-reviewed publications.  
37  
38

39  
40 The primary output of this study is the PtDA, available in print. This will then be evaluated for  
41  
42 effectiveness in a larger study, outside the costings of this grant application. Once fully  
43  
44 evaluated it will be promoted more widely through social media, charity websites,  
45  
46 professional organisations and academic sources.  
47  
48  
49

50  
51  
52  
53 Figure 1: Summary of the study stages

54  
55  
56 Figure 2: Summary of stage 3 – Evaluation study  
57  
58  
59  
60

## References

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *The Lancet*. 2012 August;380(9853):1606-19.
2. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2006 Apr; 19(2):CD000543.
3. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2005 Dec;353(23):2462-76.
4. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2012 Feb;142(2):257-65.
5. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med*. 2017 May;376(18):1723-36.
6. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011 May;140(6):1785-94.
7. Bohl JL, Sobba K. Indications and Options for Surgery in Ulcerative Colitis. *Surg Clin North Am*. 2015 Dec;95(6):1211-32, vi.
8. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. *Gut*. 2012 Mar;61(3):459-65.
9. Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Aliment Pharmacol Ther*. 2016 Oct;44(8):807-16.
10. Allison M, Lindsay J, Gould D, Kelly D. Surgery in young adults with inflammatory bowel disease: a narrative account. *Int J Nurs Stud*. 2013 Nov;50(11):1566-75.
11. Styliński R, Alzubedi A, Rudzki S. Parastomal hernia - current knowledge and treatment. *Wideochir Inne Tech Maloinwazyjne*. 2018 Mar;13(1):1-8.
12. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med*. 2012 Oct;27(10):1361-7.
13. sitecore\. Consent: Supported Decision-Making - a good practice guide — Royal College of Surgeons [Internet]. Royal College of Surgeons. [cited 2018 Nov 7]. Available from: <https://www.rcseng.ac.uk/library-and-publications/rcs-publications/docs/consent-good-practice-guide/>
14. Ulcerative colitis: management | Guidance and guidelines | NICE. [cited 2018 Nov 7]; Available from: <https://www.nice.org.uk/guidance/cg166/evidence>
15. Byrne CM, Tan K-K, Young JM, Selby W, Solomon MJ. Patient and clinician preferences for surgical and medical treatment options in ulcerative colitis. *Colorectal Dis*. 2014 Apr;16(4):285-92.
16. Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJCM, Kroep JR, Quarles van Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer

- 1  
2  
3 treatment: A potential barrier to shared decision making. *Eur J Cancer*. 2016 Oct;66:55–66.  
4  
5 17. Siegel CA. Embracing the internet for progress in shared decision-making. *Inflamm Bowel Dis*.  
6 2007 Dec;13(12):1579–80.  
7  
8 18. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing  
9 health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017 Apr  
10 12;4:CD001431.  
11  
12 19. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for  
13 people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2011 Oct  
14 5;(10):CD001431.  
15  
16 20. Bekker HL, Winterbottom AE, Butow P, Dillard AJ, Feldman-Stewart D, Fowler FJ, et al. Do  
17 personal stories make patient decision aids more effective? A critical review of theory and  
18 evidence. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S9.  
19  
20 21. Knops AM, Legemate DA, Goossens A, Bossuyt PMM, Ubbink DT. Decision aids for patients  
21 facing a surgical treatment decision: a systematic review and meta-analysis. *Ann Surg*. 2013  
22 May;257(5):860–6.  
23  
24 22. Patient Decision Aids - Ottawa Hospital Research Institute [Internet]. [cited 2018 Nov 7].  
25 Available from: <https://decisionaid.ohri.ca/AZlist.html>.  
26  
27 23. Baker DM, Marshall JH, Lee MJ, Jones GL, Brown SR, Lobo AJ. A Systematic Review of Internet  
28 Decision-Making Resources for Patients Considering Surgery for Ulcerative Colitis. *Inflamm*  
29 *Bowel Dis*. 2017 Aug;23(8):1293–300.  
30  
31 24. Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, van der Weijden T. A systematic  
32 development process for patient decision aids. *BMC Med Inform Decis Mak*. 2013 Nov 29;13  
33 Suppl 2:S2.  
34  
35 25. Jones GL, Hughes J, Mahmoodi N, Greenfield D, Brauten-Smith G, Skull J, et al. Observational  
36 study of the development and evaluation of a fertility preservation patient decision aid for  
37 teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research  
38 protocol. *BMJ Open*. 2017 Mar 13;7(3):e013219.  
39  
40 26. Baker DM, Lee MJ, Jones GL, Brown SR, Lobo AJ. The Informational Needs and Preferences of  
41 Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study. *Inflamm*  
42 *Bowel Dis*. 2017 Dec 19;24(1):179–90.  
43  
44 27. Joseph-Williams N, Newcombe R, Politi M, Durand M-A, Sivell S, Stacey D, et al. Toward  
45 Minimum Standards for Certifying Patient Decision Aids: A Modified Delphi Consensus Process.  
46 *Med Decis Making*. 2014 Aug;34(6):699–710.  
47  
48 28. Burton M, Kilner K, Wyld L, Lifford KJ, Gordon F, Allison A, et al. Information needs and decision-  
49 making preferences of older women offered a choice between surgery and primary endocrine  
50 therapy for early breast cancer. *Psychooncology*. 2017 Dec;26(12):2094–100.  
51  
52 29. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res*. 1997  
53 Autumn;29(3):21–43.  
54  
55 30. Abhyankar P, Volk RJ, Blumenthal-Barby J, Bravo P, Buchholz A, Ozanne E, et al. Balancing the  
56 presentation of information and options in patient decision aids: an updated review. *BMC Med*  
57  
58  
59  
60

- 1  
2  
3 Inform Decis Mak. 2013 Nov 29;13 Suppl 2:S6.  
4  
5 31. Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell P. A systematic review on communicating  
6 with patients about evidence. *J Eval Clin Pract*. 2006 Feb;12(1):13–23.  
7  
8 32. Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PKJ, et al. Presenting  
9 quantitative information about decision outcomes: a risk communication primer for patient  
10 decision aid developers. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S7.  
11  
12 33. Barratt A, Trevena L, Davey HM, McCaffery K. Use of decision aids to support informed choices  
13 about screening. *BMJ*. 2004 Aug 28;329(7464):507–10.  
14  
15 34. Fagerlin A, Pignone M, Abhyankar P, Col N, Feldman-Stewart D, Gavaruzzi T, et al. Clarifying  
16 values: an updated review. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S8.  
17  
18 35. Ley P, Florio T. The use of readability formulas in health care. *Psychol Health Med*. 1996 Feb  
19 1;1(1):7–28.  
20  
21 36. How to Write Easy-to-Read Health Materials: MedlinePlus [Internet]. [cited 2018 Nov 15].  
22 Available from: <https://medlineplus.gov/etr.html>  
23  
24 37. Doak LG, Doak CC, Meade CD. Strategies to improve cancer education materials. *Oncol Nurs*  
25 *Forum*. 1996 Sep;23(8):1305–12.  
26  
27 38. Baker SE, Edwards R, Doidge M. How many qualitative interviews is enough?: expert voices and  
28 early career reflections on sampling and cases in qualitative research. In: *How many qualitative*  
29 *interviews is enough? Expert voices and early career reflections on sampling and cases in*  
30 *qualitative research*. National Centre for Research Methods, Southampton, UK: National Centre  
31 for Research Methods, Southampton; 2012.  
32  
33 39. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An Experiment with Data  
34 Saturation and Variability. *Field methods*. 2006 Feb 1;18(1):59–82.  
35  
36 40. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006 Jan 1;3(2):77–  
37 101.  
38  
39 41. Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a  
40 preparation for decision making scale. *Patient Educ Couns*. 2010 Jan;78(1):130–3.  
41  
42 42. McGillion MH, Carroll SL, Metcalfe K, Arthur HM, Victor JC, McKelvie R, et al. Development of a  
43 patient decision aid for people with refractory angina: protocol for a three-phase pilot study.  
44 *Health Qual Life Outcomes*. 2014 Jun 11;12:93.  
45  
46 43. Elwyn G, Scholl I, Tietbohl C, Mann M, Edwards AGK, Clay C, et al. “Many miles to go ...”: a  
47 systematic review of the implementation of patient decision support interventions into routine  
48 clinical practice. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S14.  
49  
50 44. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the  
51 Spielberger State—Trait Anxiety Inventory (STAI). *British Journal of Clinical Psychology*.  
52 1992;31(3):301–6.  
53  
54 45. Stage of Decision Making - Evaluation Measures - Patient Decision Aids - Ottawa Hospital  
55 Research Institute [Internet]. [cited 2018 Nov 7]. Available from:  
56 [https://decisionaid.ohri.ca/eval\\_stage.html](https://decisionaid.ohri.ca/eval_stage.html)  
57  
58  
59  
60

- 1  
2  
3 46. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan;15(1):25–  
4 30.  
5  
6 47. "Carrying Out Qualitative Analysis" IN: Ritchie, J. and Lewis, J. - Qualitative research practice: a  
7 guide for social science students and researchers, pp. 219-262 | Manchester Metropolitan  
8 University [Internet]. [cited 2018 Nov 15]. Available from:  
9 <https://mmu.rl.talis.com/items/66AF60B5-E551-9DB6-49A9-F7A51E02C076.html>  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Author Contributions

AJL is the chief investigator and secured grant funding with assistance from DMB, MJL, GLJ and SRB in formulating the protocol and attending grant interviews. AJL, DMB, MJL, GLJ, SRB, SS and SRB provided intellectual input into the protocol for the grant application. AJL, DMB, MJL, GLJ, SRB, SS, SRB, AMF, KR, RW provided intellectual input and study design for the final protocol for the study.

## Funding Statement

This work was funded by the Crohn's and Colitis UK 'Living with IBD' research award for 2018. This was awarded to the research group, with Professor Alan Lobo as the principal investigator.

## Competing interests

Alan Lobo is a consultant, advisory board member or received lecture fees for MSD, Janssen, Pfizer, Takeda Pharma, Abbvie, Dr Falk, Shield Pharmaceuticals, and Vifor Pharma. The other authors have no conflicts of interest to declare.




Figure 1: Summary of the study stages

281x93mm (96 x 96 DPI)




Figure 2: Summary of stage 3 – Evaluation study

148x165mm (96 x 96 DPI)



# BMJ Open

**Development and evaluation of a patient decision aid for patients considering ongoing medical or surgical treatment options for ulcerative colitis using a mixed-methods approach: protocol for DISCUSS study.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031845.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Oct-2019
Complete List of Authors:	Baker, Daniel; Leicester Medical School, Lee, Matthew; Sheffield Teaching Hospitals NHS Foundation Trust Folan, Anne-Mairead; Leeds Beckett University, Department of Psychology Blackwell, Sue ; ACPGBI patient Liaison group Robinson, Kerry; Sheffield Teaching Hospitals NHS Foundation Trust, Inflammatory Bowel Disease nurse specialist Wootton, Rebecca; Sheffield Teaching Hospitals NHS Foundation Trust, Stoma Care Specialist Nurse Sebastian, Shaji; Hull and East Yorkshire Hospitals NHS Trust, Department of Gastroenterology Brown, Steven; Sheffield Teaching Hospitals NHS Foundation Trust, Department of General Surgery Jones, Georgina; Leeds Beckett University Faculty of Health and Social Sciences, Lobo, Alan; Sheffield Teaching Hospitals NHS Foundation Trust, Gastroenterology Unit, P Floor
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Ulcerative Colitis, Decision Making, SURGERY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title:** Development and evaluation of a patient decision aid for patients considering  
4 ongoing medical or surgical treatment options for ulcerative colitis using a mixed-methods  
5 approach: protocol for DISCUSS study.  
6  
7

8  
9 **Authors:** Baker DM, Lee MJ, Folan AM, Blackwell S, Robinson K, Wootton R, Sebastian S,  
10 Brown SR, Jones GL, Lobo AJ  
11  
12

13  
14 **Correspondence author:**

15  
16 Professor Alan Lobo, [alan.loblo@nhs.net](mailto:alan.loblo@nhs.net) , Telephone: 0114 2712353  
17

18 Gastroenterology Unit, P Floor, Royal Hallamshire Hospital, Sheffield, S10 2JF  
19  
20

21 **Co-authors:**

22  
23 Mr Daniel M Baker, Medical School, University of Leicester, Leicester, UK  
24

25  
26 Miss Sue Blackwell, Patient Liaison Group, ACPGBI  
27

28  
29 Professor Steven R Brown, Department of General Surgery, Sheffield Teaching Hospitals,  
30 Sheffield, UK  
31

32  
33 Miss Anne-Mairead Folan, Department of Psychology, School of Social Sciences, Leeds  
34 Beckett University, Leeds, UK  
35

36  
37 Professor Georgina L Jones, Department of Psychology, School of Social Sciences, Leeds  
38 Beckett University, Leeds, UK  
39

40  
41 Mr Matthew J Lee, Department of General Surgery, Sheffield Teaching Hospitals, Sheffield,  
42 UK  
43

44  
45 Professor Shaji Sebastian, Department of Gastroenterology, Hull University Teaching  
46 Hospitals NHS Trust, Hull, UK  
47

48  
49 Mrs Kerry Robinson, Inflammatory Bowel Disease Nurse Specialist, Sheffield Teaching  
50 Hospitals, Sheffield, UK  
51

52  
53 Mrs Rebecca Wootton, Stoma Care Specialist Nurse, Sheffield Teaching Hospitals, Sheffield,  
54 UK  
55  
56  
57  
58  
59  
60

1  
2  
3 Professor Alan J. Lobo, Academic Dept of Gastroenterology, University of Sheffield and  
4 Sheffield Teaching Hospitals NHS Foundation Trust.  
5  
6

7 **Word count: 3245**  
8  
9

## 10 **Abstract**

11  
12

13 Introduction: Approximately 20-30% of patients with Ulcerative Colitis (UC) require surgery,  
14 the majority of these being elective due to chronic symptoms refractory to medical  
15 treatment. The decision for surgery is difficult and dependant on patient preferences.  
16 Current resources for patients considering surgery have been found not to meet minimum  
17 international standards. The overall aim of the 'DISCUSS' study is to develop and evaluate a  
18 new Patient Decision Aid (PtDA) for patients considering surgery for UC created in line with  
19 international minimum standards.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Methods and analysis: This is a prospective mixed-methods study of adults (18+ years) who  
32 are considering surgical intervention for UC across two regional centres in Yorkshire, UK.  
33 This study is in 3 stages. In stage 1 we will develop the PtDA and its content via systematic  
34 reviews and a patient questionnaire. In stage 2 we will assess the face validity of the PtDA  
35 using mixed-methods on key stakeholders using both semi-structured interviews and  
36 questionnaires, following which the PtDA will be refined. In stage 3 we will assess the  
37 acceptability of using the PtDA in clinical practice. This will use a mixed-methods approach  
38 on clinicians and patients who are considering undergoing elective surgery. Questionnaires  
39 including the Preparation for Decision Making Scale, a measure of anxiety and decisional  
40 conflict will be analysed at 2 timepoints using paired sample t-tests and confidence  
41 intervals. Interviews with patients and clinicians will be analysed using thematic analysis.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Ethics and Dissemination: Research Ethics approval from North East – Tyne & Wear South  
4  
5  
6 Research Ethics Committee(Ref: 19/NE/0073) and Health Research Authority approval (Ref:  
7  
8 257044) have been granted. Results will be published in open access peer-reviewed  
9  
10 journals, presented and conferences and distributed through the Crohn's and Colitis UK  
11  
12 charity. External endorsement will be sought from the International Patient Decision Aid  
13  
14 Standards (IPDAS) Collaboration inventory of PtDAs.  
15  
16

### 17 18 **Article summary;**

19  
20  
21  
22 Strengths and limitations of this study:

- 23  
24  
25 ● This study will develop and evaluate a new patient decision aid for patients  
26  
27 considering surgery for ulcerative colitis which will meet minimum international  
28  
29 standards. This is a preliminary pilot study.
- 30  
31  
32 ● This study will provide evidence for its acceptability and value to patients in routine  
33  
34 clinical practice when considering surgery for ulcerative colitis.
- 35  
36  
37 ● This study will also provide evidence of the acceptability of the patient decision aid  
38  
39 from the clinicians' perspective and the feasibility of use in routine clinical practice.
- 40  
41  
42 ● This study will not provide evidence on the value of the PtDA nationally. However, it  
43  
44 will provide evidence across two large regional centres in Yorkshire which may be  
45  
46 utilised to form the study design of a national evaluation.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

### The rationale for the study

Ulcerative colitis (UC) is a chronic, relapsing and remitting inflammatory condition of the colon and rectum. It causes debilitating symptoms such as bleeding per rectum, increased stool frequency, abdominal pain and tenesmus (1). Symptoms can be managed using medical therapies such as aminosalicylates, corticosteroids, biologics agents (anti-tumour necrosis factor- $\alpha$  or anti-integrin) and tofacitinib (2-5). However approximately 20-30% of patients with UC will require surgery during their disease course (6). A minority of patients will require emergency surgery – but the majority of patients have elective surgery due to chronic symptoms, refractory to medical treatment (7). Individuals therefore make a choice, or series of choices, to continue with medical treatment or undergo surgery. Surgery may be undertaken with the intention of proceeding to further reconstructive surgery to restore continuity of the gastrointestinal tract, or remaining with a permanent ileostomy.

The decision to opt for elective surgery is described as preference-sensitive as the preferred treatment option is dependent on patient preferences due to clinical equipoise between the options (8). The same can be said for the decision between reconstructive surgery versus permanent ileostomy. The impact on lifestyle of these two choices cannot be understated – reconstructive surgery will avoid a stoma, with an acceptance of potential complications such as increased stool frequency, pouchitis or faecal incontinence (9). A stoma may offer more control over excretory functions, but is associated with complications such as parastomal hernia, as well as psychological sequelae (10,11). When selecting a treatment option, it is clear that the patient must select the option based on their preferences.

1  
2  
3  
4  
5  
6 Shared decision-making is a process whereby clinicians share information about treatment  
7  
8 options, empowering the patient to make a decision based on their preferences (12).  
9  
10 Providing clear and balanced pre-operative information is a major prerequisite to informed  
11  
12 decision making (12,13). National Institute for Health and Care Excellence (NICE) guidelines  
13  
14 for UC emphasise the importance of providing such information, but note that no high  
15  
16 quality studies assessing the desired content of information were available on which to base  
17  
18 recommendations (14). As such clinicians lack guidance on patient informational  
19  
20 preferences on which to base discussions during consultations. Clinician preferences can be  
21  
22 misaligned with patient preferences, especially when considering surgical options for UC  
23  
24 (15), forming a barrier to decision-making in this population. Pre-operative discussions may  
25  
26 also be limited by 'implicit persuasion' – a process whereby clinicians subconsciously place  
27  
28 greater emphasis on treatment options they believe are suited to the patient (16). Lack of  
29  
30 time in clinic, as well as the lack of guidance on the content of pre-operative consultations,  
31  
32 may provide limitations in the shared decision-making process for UC patients (17).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Patient decision aids**

44  
45 Patient decision aids (PtDAs) are specially created tools which aim to improve patient  
46  
47 knowledge and aid decision-making (18,19). They are evidenced based, utilising the most  
48  
49 up-to-date clinical evidence, studies assessing patient informational preferences and  
50  
51 evidence on how patients make decisions (20). PtDAs can be used within the clinical  
52  
53 encounter, by the clinician, to provide structure to consultations, but also by the patients  
54  
55 outside the encounter to aid their deliberation – a key step to informed consent (13).  
56  
57  
58  
59  
60

1  
2  
3 A systematic review of PtDAs in surgery has illustrated their role in improving knowledge,  
4 reducing decisional conflict and increasing patient input into decision making (21). A  
5  
6 satisfactory PtDA for patients considering surgery for UC is not currently available. The  
7  
8 single aid registered on the Decision Aids Library Inventory (22) does not meet minimum  
9  
10 standards laid out by the International Patient Decision Aid Standards (IPDAS) (23), which  
11  
12 have established clear guidance for the systematic development of a PtDA (24). This can be  
13  
14 summarised into 3 stages, as previously described by members of our research group (25),  
15  
16 and forms the methodology behind this protocol. It is therefore proposed that a new PtDA  
17  
18 for patients considering surgery for UC, created in-line with minimum standards, will work  
19  
20 towards filling an informational need for both patients and clinicians (14,26).  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Aims and objectives**

30  
31  
32 The aim of this research is to develop, assess and validate a patient decision aid for patients  
33  
34 considering elective surgery for ulcerative colitis; i.e. whether to continue with their current  
35  
36 medical treatment, or whether to undergo surgery. This will also include information on the  
37  
38 different surgical options (mainly permanent stomas vs reconstructive surgery) as this may  
39  
40 influence the overall decision to undergo surgery. We will do this in line with the systematic  
41  
42 development process specified by IPDAS, ensuring the decision aid meets minimum  
43  
44 standards (24,27).  
45  
46  
47  
48  
49

50 The study objectives are to:

- 51  
52  
53 1. Develop a decision aid for use by gastroenterology and colorectal surgery teams  
54  
55 (consultant surgeons/gastroenterologists, stoma/IBD nurses) to support adult  
56  
57  
58  
59  
60

1  
2  
3 patients (>18 years of age) in their decision about elective surgery, and the surgical  
4  
5 option they may wish to opt for.

6  
7  
8 2. Assess the face validity of the decision aid to support patients make an informed  
9  
10 decision about their preferred treatment option.

11  
12  
13 3. Pilot an evaluation study for the acceptability of the decision aid in clinical practice.

14  
15 This will use a mixed methods approach to capture the views of:

- 16  
17 a. patients making the treatment decision and  
18  
19 b. gastroenterology and colorectal surgery health professionals supporting the  
20  
21 patient through their decision.  
22  
23  
24  
25

26 It is anticipated the evaluation of the PtDA will determine whether the administration of a  
27  
28 PtDA in the treatment pathway will better support patients in their treatment decisions, as  
29  
30 well as providing structure and guidance to consultations with patients.  
31  
32  
33

## 34 **METHODS AND ANALYSIS**

35  
36  
37 The methodology used for this research has been adapted from a previously published  
38  
39 protocol to develop a PtDA for women with cancer to help them make fertility preservation  
40  
41 treatment decisions (Cancer, Fertility and Me), led by a member of our research team (GLJ)  
42  
43 and funded by Yorkshire Cancer Research (S391) (25). The protocol also follows established  
44  
45 guidance from IPDAS and other recommended guidance regarding the development of PtDA  
46  
47 (24,27). The study process is summarised in figure 1.  
48  
49  
50  
51

52 A steering group with relevant expertise to support PtDA development is essential (24).  
53  
54 Therefore, a steering group was created prior to protocol development and submission for  
55  
56 grant funding to ensure all stakeholders were represented. The steering group consists of;  
57  
58 specialist surgical and gastroenterology clinicians, health psychologists with expertise in  
59  
60



1  
2  
3 decision-making, IBD/Stoma nurses, a medical student, and patient representatives. All  
4  
5 sections of the protocol have been reviewed and discussed by the steering group. The PtDA  
6  
7 will be developed across two regional centres (Sheffield Teaching Hospitals and Hull and  
8  
9 East Yorkshire Hospitals). The steering group will hold regular meetings during stage 1 to  
10  
11 decide the content and design of the aid, and will hold regular meetings at important stages  
12  
13 thereafter. Ethics approval was granted on 13<sup>th</sup> March 2019.  
14  
15  
16  
17

## 18 **Design**

### 20 Stage 1: Development of the PtDA

#### 22 *1. Validating patient informational preferences*

23  
24  
25 Our group has already carried out qualitative work exploring patient informational  
26  
27 preferences when considering surgery (26). These results will be validated on a national  
28  
29 scale by a questionnaire using established methodology (15,28). Questionnaire content will  
30  
31 include demographic data, the control preferences scale (29) and questions about the  
32  
33 preferred content and format of pre-operative information. This will provide a description of  
34  
35 whether particular demographic groups of patients are amenable to a PtDA, and the  
36  
37 preferred content and format of such an aid. Questionnaires will be disseminated to a  
38  
39 number of sites through an established network of IBD researchers. Prior to questionnaire  
40  
41 development, patients will be involved in questionnaire design and refinement via a focus  
42  
43 group held at Sheffield Teaching Hospitals. This will help make the findings generalisable  
44  
45 and ensure key concepts are included within the questionnaire.  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 *2. Synthesising the best available evidence*

55  
56  
57 This will consist of the following stages:  
58  
59  
60

1  
2  
3 a) Systematic reviews of evidence about the risks and benefits of elective surgery and  
4 continued medical management will be undertaken, as well as a systematic review  
5 on factors influencing treatment choices. A full list of inclusion and exclusion criteria  
6 for each review is listed in Supplementary appendix (Table S1, S2, S3):  
7  
8  
9  
10  
11  
12

- 13 ● A systematic review of outcomes after surgery to inform the PtDA using the  
14 best available evidence. This has been registered on the PROSPERO  
15 ([www.crd.york.ac.uk/PROSPERO](http://www.crd.york.ac.uk/PROSPERO)) database (ref:  
16 CRD42018115513). Methodology will include the procedures subtotal  
17 colectomy with permanent end ileostomy, proctocolectomy, ileal-anal pouch  
18 anastomosis and ileorectal anastomosis. Ileorectal anastomosis will be  
19 included in the PtDA as our research group notes it is a procedure that is  
20 offered in some UK centres, as well as in centres outside the UK. Its inclusion  
21 is with the caveat that some centres may not offer this operation, and this  
22 will be noted in the aid. Primary outcome will be quality of life, with  
23 secondary outcomes covering a wide range of early and late complications  
24 after surgery.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42 ● Systematic review of risks and benefits of continued medical treatment. This  
43 will inform the decision aid so that the consequences of continued medical  
44 treatment – positive and adverse – can be quantified for patients facing this  
45 choice. This has been registered on PROSPERO (ref: CRD42019126186).  
46  
47  
48  
49  
50  
51  
52 ● Systematic review of the factors that may facilitate or hinder patients with  
53 UC to make medical and surgical treatment choices (e.g. possible fear of a  
54 stoma) to ensure these elements are captured and addressed in the new  
55 resource. This has been registered on PROSPERO (ref: CRD42019125193).  
56  
57  
58  
59  
60

- 1  
2  
3 b) Focus groups with expert clinicians, nurses and patients regarding the optimum time  
4 to introduce the PtDA into the treatment pathway, as well as the optimum content  
5  
6  
7  
8 for each group. This will be via a PPI day at Sheffield Teaching Hospitals.  
9

### 10 11 *3. Drafting the PtDA*

12  
13  
14 Once the evidence has been synthesised, the steering group will meet to decide the content  
15 of the aid. The PtDA will be created using IPDAS guidance (24,27); including guidance on  
16 balancing options (30), risk presentation (30–33), eliciting patient values (34), use of patient  
17 stories (18), and enabling readability (35,36), something found to be poor in the UC patient  
18 literature (23).  
19  
20  
21  
22  
23  
24  
25

26  
27 The content of the aid will be guided by the informational preferences studies and  
28 systematic reviews of evidence we complete. Significant risks, benefits and outcomes, and  
29 their associated probabilities from our systematic reviews will be included. Common topics  
30 of informational preferences will be discussed by the group, and a consensus established on  
31 the inclusion. The composition of the group, with both expert clinicians and patients, will  
32 help to develop content that meets the requirements of both patients and healthcare  
33 professionals.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

#### 45 **Stage 2: Face validity study**

46  
47  
48 The aim of this stage is to assess the PtDA for comprehension, feasibility and acceptability  
49 using key stakeholders - sometimes referred as learner verification or alpha testing (24,37).  
50  
51 This will be done with both clinicians and patients, using qualitative methodology, and  
52 according to an established protocol, with which we have extensive experience. This will be  
53 undertaken across two large sites (Sheffield and Hull).  
54  
55  
56  
57  
58  
59  
60

### *Sample*

A purposive sample of healthcare professionals and patients not involved in the steering group will be invited to take part in the study. Purposive sampling has been chosen to ensure recruitment of a representative sample of both healthcare professionals and patients. The HCP sample will include colorectal surgeons, gastroenterologists, IBD nurses and Stoma nurses. The patient sample will include those who opted for surgery, those who considered but declined surgery and those currently deliberating treatment options. We expect a sample size of 20 participants, with a minimum of 10 healthcare professionals and 10 patients, will be enough based on previous studies and experience (25). However, sample size will be guided by data saturation, which is in-line with good qualitative methods (38–40).

### *Recruitment*

Patients will be identified through the services at the two clinical centres by clinicians and nurses. We will also advertise stage 2 of the study through the Crohn's and Colitis UK forums. Following this the contact details for consenting patients will be passed on to a trained researcher and those willing to participate will be sent the PtDA for review. Healthcare professionals will be recruited from the study sites through purposive sampling. All contact details will be stored securely at either Sheffield Teaching Hospitals or Leeds Beckett University.

### *Data collection*

### *Qualitative*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Consenting clinicians and patients will be posted the PtDA and given 1-2 weeks to assess the aid, with a telephone interview taking place at the end of the time period. Patients and clinicians will provide verbal feedback on the aid, focussing on its comprehensibility and ease of use. An interview schedule will be created *a priori* by expert members of the steering group. Interviews will be audio recorded, digitalised, and transcribed for analysis.

### *Quantitative*

Patients will also be asked to complete a Preparation for Decision-Making Questionnaire. The Preparation for Decision-Making Questionnaire is a 10-item measure which will provide a score on a scale of 0-100 (41). The higher the score, the higher the perceived levels of preparation for decision-making - which will provide a validated quantitative measure of how individuals view the usefulness of the PtDA (41).

### *Data analysis*

Interviews will be transcribed and coded using NVivo 11 Computer-Assisted Qualitative Data Analysis Software (QSR International, Australia). Analysis will use an inductive thematic approach, outlined by Braun and Clarke using a systematic five-step approach: familiarisation, generating initial codes, searching for themes, reviewing themes, and defining and naming themes (40). The themes actively generated by the researchers from the data will be discussed by the steering group.

The steering group will subsequently refine the aid based on the results of this stage. If there are significant changes required, a second face validity study will be undertaken before progression to stage 3.

Stage 3: Evaluation study

1  
2  
3 The aim of this pilot is to field test the PtDA in clinical practice, as there may be clinical  
4 contextual factors impacting the PtDA. This is typically referred to as beta testing (24). This  
5 will follow a mixed-methods approach across the same two sites as in stage 2. We aim to  
6 recruit 15 patients at each site for a minimum sample size of 30 – comparable with other  
7 PtDA pilots in the literature (42). A summary of stage 3 is provided in figure 2.  
8  
9  
10  
11  
12  
13  
14  
15

### 16 *Quantitative*

17  
18  
19 *Sample and recruitment:* All patients over the age of 18 that receive consultation about the  
20 possibility of undergoing elective surgery will be included. This includes consultations with  
21 clinicians and specialist nurses. We will use the referral model for implementing PtDA - a  
22 process where the clinician mentions the PtDA to eligible patients during consultation about  
23 treatment options, and indicates the clinical researchers will discuss the study following the  
24 consultation should the patient consent to involvement (43). Eligible patients identified by  
25 the clinical team will be invited to participate by the researcher(s) with the clinical team  
26 immediately following the consultation if they are present, or within a week if the patient  
27 consents to contact outside the clinical setting by a member of the research team.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 *Data measures and collection:* Patients will be asked to complete a series of questionnaires  
43 at baseline (1<sup>st</sup> clinic appointment) before administration of the PtDA. Patients will be  
44 instructed not to open or view the PtDA before completion of the questionnaires at  
45 baseline. Patients will then complete the same questionnaires at time-point 1 (immediately  
46 before the 2<sup>nd</sup> clinic appointment). Questionnaires will include a measure of anxiety (STAI-6)  
47 (44), Stage of Decision-Making (45) and Decisional Conflict Scale (46) as recommended by  
48 IPDAS (24). All questionnaires will provide a quantitative measure to allow comparison  
49 before and after use of the PtDA.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *Analysis:* Summary statistics will be reported for demographics and other relevant  
4 indicators. For decisional outcome measures we will use paired sample t-tests to calculate  
5 mean changes from baseline to time-point 1. Confidence intervals will be set at 95% *a priori*,  
6 meaning values will be significant if  $p \leq 0.05$ .  
7  
8  
9  
10  
11

### 12 13 *Qualitative*

14  
15  
16 *Sample and recruitment:* Healthcare professionals and patients will be asked to take part in  
17 semi-structured interviews. We will undertake 10 interviews with patients and 10 with  
18 healthcare professionals (IBD/stoma nurses, gastroenterology and surgical clinicians),  
19 although this will be guided by data saturation, in line with established protocols in  
20 qualitative research (38,40). The interviews will give a deeper insight into the experience of  
21 using the aid from a patient and clinician perspective in clinical practice. Clinician interviews  
22 will also explore views regarding the timing of the aid in the treatment pathway,  
23 establishing if the time previously eliciting in stage 1 is also the optimum time for additional  
24 sites. Patients will be recruited using purposive sampling from the sample of 30 that have  
25 taken part in the quantitative analysis of stage 3. Prior to interview patients will receive an  
26 information sheet, and on the day of interview the patient will be issued a consent form  
27 which will be co-signed with the interviewer.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 *Data collection:* An interview transcript will be created by expert members of the steering  
47 group *a priori*. Questions will be adapted from the transcript used in stage 2, with additional  
48 questions to add depth and clarity into the interpretation of the quantitative results.  
49 Questions will also focus on the PtDAs usefulness in helping the patient decide between  
50 treatment options.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *Analysis:* All interviews will be transcribed and coded as per the same methods in stage 2.  
4  
5 Framework analysis, an analysis designed specifically for applied health and policy research  
6  
7 (47), will be utilised to identify recurrent themes. Recurrent themes will be discussed with  
8  
9 the steering group and subsequent refinement of the PtDA will take place.  
10  
11  
12

### 13 **Patient and Public Involvement**

14  
15  
16 A patient representative who had prior experience of the decision at question in our PtDA  
17  
18 was recruited to the steering committee prior to protocol development. Our representative  
19  
20 contributed to overall protocol development, particularly the feasibility of stage 3 to the  
21  
22 public. It was anticipated our patient representative would contribute heavily to the design  
23  
24 and format of the PtDA, commenting on readability, layout and presentation of information.  
25  
26 Patient representative did not contribute to study recruitment. Patients will also be involved  
27  
28 in questionnaire development (stage 1) and design via a focus group.  
29  
30  
31  
32  
33

## 34 **ETHICS AND DISSEMINATION**

### 35 **Ethical considerations**

36  
37  
38 Research Ethics approval from North East – Tyne & Wear South Research Ethics Committee  
39  
40 (Ref: 19/NE/0073) and Health Research Authority approval (Ref: 257044) has been granted.  
41  
42  
43 Written, signed consent will be obtained from all participants at stages where it is  
44  
45 necessary. Participants will have the right to withdraw from the research process at any  
46  
47 time throughout the study. All interviews will be kept strictly confidential and patients and  
48  
49 healthcare professionals will be given a study ID number to maintain this confidentiality.  
50  
51  
52 Participation in this study will not interfere with usual patient care.  
53  
54  
55  
56  
57  
58

### 59 **Dissemination**



1  
2  
3 This a multidisciplinary, collaborative project with clinicians and patients. This will allow us  
4  
5 to disseminate the research and its milestones into both the NHS and the wider healthcare  
6  
7 community through a variety of local, national and international forums such as charities  
8  
9 and international meetings. We will also seek to index an online version of the PtDA in the  
10  
11 Decision Aid Library Inventory once we have completed and analysed the paper version. We  
12  
13 will also seek to index the NHS library of decision aids. A web-based version of the PtDA will  
14  
15 also allow dissemination through the internet which is widely accessible to patients  
16  
17 worldwide. Social media such as twitter and blogs can also be utilised to signpost the  
18  
19 availability of the instrument to both clinicians and patients.  
20  
21  
22  
23

24  
25 We plan to impact the academic and clinical community more widely through a combination  
26  
27 of conference presentations and peer-reviewed publications.  
28  
29

30  
31 The primary output of this study is the PtDA, available in print. This will then be evaluated  
32  
33 for effectiveness in a larger study, outside the costings of this grant application. Once fully  
34  
35 evaluated it will be promoted more widely through social media, charity websites,  
36  
37 professional organisations and academic sources.  
38  
39  
40  
41  
42  
43  
44

45 Figure 1: Summary of the study stages  
46

47  
48 Figure 2: Summary of stage 3 – Evaluation study  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *The Lancet*. 2012 August;380(9853):1606-19.
2. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2006 Apr; 19(2):CD000543.
3. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2005 Dec;353(23):2462-76.
4. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2012 Feb;142(2):257-65.
5. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med*. 2017 May;376(18):1723-36.
6. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011 May;140(6):1785-94.
7. Bohl JL, Sobba K. Indications and Options for Surgery in Ulcerative Colitis. *Surg Clin North Am*. 2015 Dec;95(6):1211-32, vi.
8. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. *Gut*. 2012 Mar;61(3):459-65.
9. Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Aliment Pharmacol Ther*. 2016 Oct;44(8):807-16.
10. Allison M, Lindsay J, Gould D, Kelly D. Surgery in young adults with inflammatory bowel disease: a narrative account. *Int J Nurs Stud*. 2013 Nov;50(11):1566-75.
11. Styliński R, Alzubedi A, Rudzki S. Parastomal hernia - current knowledge and treatment. *Wideochir Inne Tech Maloinwazyjne*. 2018 Mar;13(1):1-8.
12. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med*. 2012 Oct;27(10):1361-7.
13. sitecore\. Consent: Supported Decision-Making - a good practice guide — Royal College of Surgeons [Internet]. Royal College of Surgeons. [cited 2018 Nov 7]. Available from: <https://www.rcseng.ac.uk/library-and-publications/rcs-publications/docs/consent-good-practice-guide/>
14. Ulcerative colitis: management | Guidance and guidelines | NICE. [cited 2018 Nov 7]; Available from: <https://www.nice.org.uk/guidance/cg166/evidence>
15. Byrne CM, Tan K-K, Young JM, Selby W, Solomon MJ. Patient and clinician preferences for surgical and medical treatment options in ulcerative colitis. *Colorectal Dis*. 2014 Apr;16(4):285-92.
16. Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJCM, Kroep JR, Quarles van Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer

- 1  
2  
3 treatment: A potential barrier to shared decision making. *Eur J Cancer*. 2016 Oct;66:55–66.  
4  
5  
6 17. Siegel CA. Embracing the internet for progress in shared decision-making. *Inflamm Bowel Dis*.  
7 2007 Dec;13(12):1579–80.  
8  
9 18. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing  
10 health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017 Apr  
11 12;4:CD001431.  
12  
13 19. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for  
14 people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2011 Oct  
15 5;(10):CD001431.  
16  
17 20. Bekker HL, Winterbottom AE, Butow P, Dillard AJ, Feldman-Stewart D, Fowler FJ, et al. Do  
18 personal stories make patient decision aids more effective? A critical review of theory and  
19 evidence. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S9.  
20  
21 21. Knops AM, Legemate DA, Goossens A, Bossuyt PMM, Ubbink DT. Decision aids for patients  
22 facing a surgical treatment decision: a systematic review and meta-analysis. *Ann Surg*. 2013  
23 May;257(5):860–6.  
24  
25 22. Patient Decision Aids - Ottawa Hospital Research Institute [Internet]. [cited 2018 Nov 7].  
26 Available from: <https://decisionaid.ohri.ca/AZlist.html>.  
27  
28 23. Baker DM, Marshall JH, Lee MJ, Jones GL, Brown SR, Lobo AJ. A Systematic Review of Internet  
29 Decision-Making Resources for Patients Considering Surgery for Ulcerative Colitis. *Inflamm*  
30 *Bowel Dis*. 2017 Aug;23(8):1293–300.  
31  
32 24. Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, van der Weijden T. A systematic  
33 development process for patient decision aids. *BMC Med Inform Decis Mak*. 2013 Nov 29;13  
34 Suppl 2:S2.  
35  
36 25. Jones GL, Hughes J, Mahmoodi N, Greenfield D, Brauten-Smith G, Skull J, et al. Observational  
37 study of the development and evaluation of a fertility preservation patient decision aid for  
38 teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research  
39 protocol. *BMJ Open*. 2017 Mar 13;7(3):e013219.  
40  
41 26. Baker DM, Lee MJ, Jones GL, Brown SR, Lobo AJ. The Informational Needs and Preferences of  
42 Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study. *Inflamm*  
43 *Bowel Dis*. 2017 Dec 19;24(1):179–90.  
44  
45 27. Joseph-Williams N, Newcombe R, Politi M, Durand M-A, Sivell S, Stacey D, et al. Toward  
46 Minimum Standards for Certifying Patient Decision Aids: A Modified Delphi Consensus Process.  
47 *Med Decis Making*. 2014 Aug;34(6):699–710.  
48  
49 28. Burton M, Kilner K, Wyld L, Lifford KJ, Gordon F, Allison A, et al. Information needs and decision-  
50 making preferences of older women offered a choice between surgery and primary endocrine  
51 therapy for early breast cancer. *Psychooncology*. 2017 Dec;26(12):2094–100.  
52  
53 29. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res*. 1997  
54 Autumn;29(3):21–43.  
55  
56 30. Abhyankar P, Volk RJ, Blumenthal-Barby J, Bravo P, Buchholz A, Ozanne E, et al. Balancing the  
57 presentation of information and options in patient decision aids: an updated review. *BMC Med*  
58  
59  
60

- 1  
2  
3 Inform Decis Mak. 2013 Nov 29;13 Suppl 2:S6.  
4  
5 31. Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell P. A systematic review on communicating  
6 with patients about evidence. *J Eval Clin Pract*. 2006 Feb;12(1):13–23.  
7  
8 32. Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PKJ, et al. Presenting  
9 quantitative information about decision outcomes: a risk communication primer for patient  
10 decision aid developers. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S7.  
11  
12 33. Barratt A, Trevena L, Davey HM, McCaffery K. Use of decision aids to support informed choices  
13 about screening. *BMJ*. 2004 Aug 28;329(7464):507–10.  
14  
15 34. Fagerlin A, Pignone M, Abhyankar P, Col N, Feldman-Stewart D, Gavaruzzi T, et al. Clarifying  
16 values: an updated review. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S8.  
17  
18 35. Ley P, Florio T. The use of readability formulas in health care. *Psychol Health Med*. 1996 Feb  
19 1;1(1):7–28.  
20  
21 36. How to Write Easy-to-Read Health Materials: MedlinePlus [Internet]. [cited 2018 Nov 15].  
22 Available from: <https://medlineplus.gov/etr.html>  
23  
24 37. Doak LG, Doak CC, Meade CD. Strategies to improve cancer education materials. *Oncol Nurs*  
25 *Forum*. 1996 Sep;23(8):1305–12.  
26  
27 38. Baker SE, Edwards R, Doidge M. How many qualitative interviews is enough?: expert voices and  
28 early career reflections on sampling and cases in qualitative research. In: How many qualitative  
29 interviews is enough? Expert voices and early career reflections on sampling and cases in  
30 qualitative research. National Centre for Research Methods, Southampton, UK: National Centre  
31 for Research Methods, Southampton; 2012.  
32  
33 39. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An Experiment with Data  
34 Saturation and Variability. *Field methods*. 2006 Feb 1;18(1):59–82.  
35  
36 40. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006 Jan 1;3(2):77–  
37 101.  
38  
39 41. Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a  
40 preparation for decision making scale. *Patient Educ Couns*. 2010 Jan;78(1):130–3.  
41  
42 42. McGillion MH, Carroll SL, Metcalfe K, Arthur HM, Victor JC, McKelvie R, et al. Development of a  
43 patient decision aid for people with refractory angina: protocol for a three-phase pilot study.  
44 *Health Qual Life Outcomes*. 2014 Jun 11;12:93.  
45  
46 43. Elwyn G, Scholl I, Tietbohl C, Mann M, Edwards AGK, Clay C, et al. “Many miles to go ...”: a  
47 systematic review of the implementation of patient decision support interventions into routine  
48 clinical practice. *BMC Med Inform Decis Mak*. 2013 Nov 29;13 Suppl 2:S14.  
49  
50 44. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the  
51 Spielberger State—Trait Anxiety Inventory (STAI). *British Journal of Clinical Psychology*.  
52 1992;31(3):301–6.  
53  
54 45. Stage of Decision Making - Evaluation Measures - Patient Decision Aids - Ottawa Hospital  
55 Research Institute [Internet]. [cited 2018 Nov 7]. Available from:  
56 [https://decisionaid.ohri.ca/eval\\_stage.html](https://decisionaid.ohri.ca/eval_stage.html)  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
46. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making*. 1995 Jan;15(1):25–30.
  47. “Carrying Out Qualitative Analysis” IN: Ritchie, J. and Lewis, J. - *Qualitative research practice: a guide for social science students and researchers*, pp. 219-262 | Manchester Metropolitan University [Internet]. [cited 2018 Nov 15]. Available from: <https://mmu.rl.talis.com/items/66AF60B5-E551-9DB6-49A9-F7A51E02C076.html>

For peer review only

## Author Contributions


AJL is the chief investigator and secured grant funding with assistance from DMB, MJL, GLJ and SRB in formulating the protocol and attending grant interviews. AJL, DMB, MJL, GLJ, SRB, SS and SB provided intellectual input into the protocol for the grant application. AJL, DMB, MJL, GLJ, SRB, SS, SB, AMF, KR, RW provided intellectual input and study design for the final protocol for the study.

## Funding Statement

This work was funded by the Crohn's and Colitis UK 'Living with IBD' research award for 2018. This was awarded to the research group, with Professor Alan Lobo as the principal investigator.

## Competing interests

Alan Lobo is a consultant, advisory board member or received lecture fees for MSD, Janssen, Pfizer, Takeda Pharma, Abbvie, Dr Falk, Shield Pharmaceuticals, and Vifor Pharma. The other authors have no conflicts of interest to declare.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

Patients of 18 years or older presenting to one of the two study sites to discuss elective surgery for Ulcerative Colitis



Patients offered opportunity to receive the PtDA in the first consultation when surgical options are discussed



Baseline (First clinic appointment)

Patients who have consented receive 'study pack' containing PtDA and questionnaires including; demographics, Stage of Decision Making Scale, Decisional Conflict Scale and STAI-6. Patients will be instructed not to complete questionnaires before reading PtDA



Timepoint 1 (Immediately before second clinic appointment)

Patients will complete three questionnaires; Stage of Decision Making Scale, Decisional Conflict Scale and STAI-6



Timepoint 2 - Qualitative Interviews

Qualitative interviews with a minimum of 10 patients to discuss experience of using the aid

Qualitative interviews with a minimum of 10 healthcare professionals to discuss feasibility of the aid in clinical practice



## Supplementary Tables

Table S1 – Surgical outcomes systematic review inclusion/exclusion criteria

Inclusion	Exclusion
Studies including patients equal to or > 18 years of age	Studies on patients <18 years of age
Surgery for Ulcerative Colitis	Case reports, editorials, review articles
Studies report <b>any</b> outcome <sup>1</sup> after surgery	Published prior to 2002 <sup>3</sup> or data collection period extending no further than 5 years before 2002 <sup>4</sup>
Procedures (performed as one-, two- or three-stages; laparoscopic, open or robotic); total and subtotal colectomy, ileal pouch-anal anastomosis (IPAA), ileo-rectal anastomosis (IRA)	Clinical guidelines
>20 patients receiving reported procedure <sup>2</sup>	<20 patients receiving reported procedure
	Non-English Language
	No reported post-operative outcomes

1. This includes short- and long-term complications, as well as quality of life measure. 2. 20 patients was the cut off as it was agreed by the steering group that studies with a smaller sample size than this could bias results. 3. 2002 was chosen as this is when biologics began to be used in clinical practice. 4. e.g. data collection period from 1998-2008.

Table S2 – Medical outcomes systematic review inclusion/exclusion criteria

Inclusion	Exclusion
Studies including patients equal to or > 18 years of age	Studies on patients <18 years of age
Medical therapy for for Ulcerative Colitis	Case reports, editorials, review articles
Studies report any outcome <sup>1</sup> of medical therapy	Published prior to 2002 or data collection period extending no further than 5 years before 2002 (See above)
Medication included <sup>1</sup> ; systemic corticosteroids, immunosuppressants (Methotrexate, azathioprine, tacrolimus), biologics (Ustekinumab, Anti-Integrins, Anti-TNFs, Tofacitinib)	Clinical guidelines
>20 patients in study	<20 patients in study
	Non-English Language

1. Aminosalicylates were not included as the steering group agreed patients at this stage of medical therapy would not be considering surgery.

Table S3 – Systematic review of decision-making factors inclusion/exclusion criteria

Inclusion	Exclusion
Studies which have reported on the facilitators and barriers to ulcerative colitis treatment decision-making for both medical and surgical treatments.	Studies on paediatric patients (defined as under 16 years of age).
Studies using qualitative, quantitative and mixed methods designs.	Studies published in any language other than English.
	Studies on inflammatory bowel disease patients where the data relating to ulcerative colitis patients is not specified separately.
	Studies which have used simulated data